Assenagon Asset Management
SLNO

Assenagon Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Assenagon Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-384,166
Closed -$17.8M – 1211
2025
Q4 		$17.8M Buy
+384,166
New +$21.1M 0.02% 385
2025
Q3 		– Sell
-250,441
Closed -$21M – 1257
2025
Q2 		$21M Sell
250,441
-184,073
-42% -$13.8M 0.03% 341
2025
Q1 		$31M Buy
+434,514
New +$21.2M 0.05% 276
2024
Q3 		– Sell
-729,841
Closed -$29.8M – 1472
2024
Q2 		$29.8M Buy
+729,841
New +$30.9M 0.07% 218

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Assenagon Asset Management's SLNO Position: Q1 2026 in Review

Assenagon Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 384,166 shares — an estimated $17.8M sold.

Assenagon Asset Management first reported a position in SLNO in Q2 2024 and held it in 4 quarters. The position peaked at $31M in Q1 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Assenagon Asset Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 384,166 Soleno Therapeutics shares in Q1 2026, an estimated $17.8M.
  • Assenagon Asset Management first reported a position in Soleno Therapeutics in Q2 2024 and held it in 4 quarters.
  • Assenagon Asset Management's Soleno Therapeutics position peaked at $31M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Assenagon Asset Management's 13F filing for Q1 2026, filed 20 Apr 2026.